Retargeting adenoviruses for therapeutic applications and vaccines

Michael A. Barry, Jeffrey D. Rubin, Shao Chia Lu

Research output: Contribution to journalReview article


Adenoviruses (Ads) are robust vectors for therapeutic applications and vaccines, but their use can be limited by differences in their in vitro and in vivo pharmacologies. This review emphasizes that there is not just one Ad, but a whole virome of diverse viruses that can be used as therapeutics. It discusses that true vector targeting involves not only retargeting viruses, but importantly also detargeting the viruses from off-target cells.

Original languageEnglish (US)
JournalFEBS Letters
StateAccepted/In press - Jan 1 2020



  • Ad serotypes
  • detargeting
  • gain of function
  • liver
  • retargeting
  • sequestration
  • serotypes

ASJC Scopus subject areas

  • Biophysics
  • Structural Biology
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Cell Biology

Cite this